Your browser doesn't support javascript.
loading
Outcomes of ABO-incompatible kidney transplantation in older patients: a national cohort study.
Kim, Deok Gie; Lee, Juhan; Kim, Myoung Soo; Kwon, Oh Jung; Jung, Cheol Woong; Lee, Kang Wook; Yang, Jaeseok; Ahn, Curie; Huh, Kyu Ha.
Afiliação
  • Kim DG; Department of Surgery, Yonsei Wonju University College of Medicine, Wonju, South Korea.
  • Lee J; Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim MS; Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
  • Kwon OJ; Department of Surgery, Hanyang University College of Medicine, Seoul, South Korea.
  • Jung CW; Department of Surgery, Korea University Anam Hospital, Seoul, South Korea.
  • Lee KW; Department of Nephrology, Chungnam National University Hospital, Daejeon, South Korea.
  • Yang J; Transplantation Center, Department of Surgery, Seoul National University Hospital, Seoul, South Korea.
  • Ahn C; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Huh KH; Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
Transpl Int ; 34(2): 290-301, 2021 02.
Article em En | MEDLINE | ID: mdl-33258121
ABSTRACT

BACKGROUND:

Outcomes of ABO-incompatible living donor kidney transplantation (ABOi LDKT) in older individuals have not been established.

METHODS:

This multicentric observational study, using data from the Korean Organ Transplantation Registry database, included 634 older patients (≥60 years) undergoing kidney transplantation. We compared clinical outcomes of ABOi LDKT (n = 80) with those of ABO-compatible LDKT (ABOc LDKT, n = 222) and deceased donor kidney transplantation (DDKT, n = 332) in older patients.

RESULTS:

Death-censored graft survival was similar between the three groups (P = 0.141). Patient survival after ABOi LDKT was similar to that after ABOc LDKT (P = 0.489) but higher than that after DDKT (P = 0.038). In multivariable analysis, ABOi LDKT was not risk factor (hazard ratio [HR] 1.73, 95% confidence interval [CI] 0.29-10.38, P = 0.548), while DDKT was significant risk factor (HR 3.49, 95% CI 1.01-12.23, P = 0.049) for patient survival. Although ABOi LDKT showed higher biopsy-proven acute rejection than ABOc LDKT, the difference was not significant after adjustment with covariates. However, ABOi LDKT was significant risk factor for infection (HR 1.66, 95% CI 1.12-2.45, P = 0.012).

CONCLUSIONS:

In older patients, ABOi LDKT was not inferior to ABOc LDKT and was superior to DDKT for patient survival. ABOi LDKT can be recommended for older patients, rather than waiting for DDKT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Rim Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Rim Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article